Supplementary Figure – Generalizability of ORIENT-11 Trial Results to a US Standard of Care Cohort with Advanced Non-Small Cell Lung Cancer

Supplementary Figure 1. Patient attrition.

Abbreviations: 1L, first line therapy; ALK, anaplastic lymphoma kinase; CNS, central nervous system; EGFR, epidermal growth factor receptor; ICI, immune checkpoint inhibitors; aNSCLC, advanced non-small cell lung cancer

^a Index date = start date of first line therapy pembrolizumab + pemetrexed + platinum

^b Positive result at any time